A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one pharmaceutically acceptable salt of glycopyrrolate, at least one corticosteroid selected from budesonide and beclomethasone dipropionate, and optionally at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof； and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).
